A practical conversation on how biotechs can read RFPs differently, avoid the fluency trap, challenge assumptions, and choose vendors that can actually deliver.
Every biotech faces this moment: the RFP looks perfect, polished, aligned, convincing. But does it actually signal readiness?
In this episode, Seuss+ CEO Kieran Engels joins Julia Vassiliadou (F2G) to break down why a beautiful proposal can mislead sponsors, what real signals of vendor readiness look like, and how biotechs can tailor the selection process to avoid costly mistakes.
Together, they unpack:
Why we confuse polish with capability
The four signals that a vendor is genuinely ready
How to challenge assumptions during bid defenses
Why risk-based thinking (ICH E6 R3) should shape sponsor decision-making
How governance, oversight, and setup determine long-term CRO success
Whether you’re selecting your first CRO or refining your next vendor strategy, this conversation gives you the tools to see beyond the surface and choose smarter.
Podden och tillhörande omslagsbild på den här sidan tillhör
Seuss+. Innehållet i podden är skapat av Seuss+ och inte av,
eller tillsammans med, Poddtoppen.
